MGRX
Mangoceuticals, Inc.
There isn't enough reported data to score MGRX yet.
MGRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
MGRX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
MGRX PE Valuation
MGRX has no meaningful PE right now: it lost money over the past year.
MGRX Forward outlook
There aren't enough analyst estimates for MGRX to show an outlook.
MGRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.55 | +$1.64 |
| Q2 2025 | -$3.85 | +$2.00 |
| Q1 2025 | -$4.63 | +$1.97 |
| Q4 2024 | -$4.84 | +$3.71 |
| Q3 2024 | -$5.19 | +$2.59 |
| Q2 2024 | -$5.85 | +$1.28 |
MGRX is still losing money, but far less than before: $3.55 per share over the past year, against $8.55 at its worst in late 2023.
MGRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $68.8K | -59% |
| Q1 2026 | $67.9K | -38% |
| Q4 2025 | $94.4K | -10% |
| Q3 2025 | $84.2K | -37% |
| Q2 2025 | $168.1K | +3% |
| Q1 2025 | $109.3K | -49% |
| Q4 2024 | $105.2K | -57% |
| Q3 2024 | $133.4K | -46% |
MGRX's revenue has slid since its 2023 peak: $68,757 last quarter, down 59% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1502% | +1632 points |
| Q1 2026 | -4607% | -167 points |
| Q4 2025 | -390% | +1204 points |
| Q3 2025 | -8953% | -7635 points |
| Q2 2025 | -3134% | -1805 points |
| Q1 2025 | -4440% | -3334 points |
| Q4 2024 | -1594% | -543 points |
| Q3 2024 | -1318% | -584 points |
MGRX's operating margin was −1502% last quarter, up 1632 points from the same quarter a year ago.
MGRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$260.5K | +$995.9K |
| Q1 2026 | -$1.3M | +$963.4K |
| Q4 2023 | -$1.7M | -$1M |
| Q3 2023 | -$1.7M | -$1.1M |
| Q2 2023 | -$1.8M | -$1.7M |
| Q1 2023 | -$1.8M | -$1.8M |
| Q4 2022 | -$690.1K | -$672.6K |
MGRX has burned cash in almost every quarter: −$4M over the past year, against −$7M the year before.
MGRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +638K shares |
| 1 year | +273% | +12.5M shares |
| 3 years | +1616% | +16.1M shares |
MGRX has 17M diluted shares, up 273% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
MGRX Net Leverage
MGRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MGRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 1.9 | Oversold |
MGRX's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
MGRX PE vs Healthcare Sector
MGRX has no meaningful PE right now: it lost money over the past year.
MGRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.31 | 42% below |
| 20 week MA | $0.40 | 55% below |
| 50 week MA | $0.46 | 61% below |
| 100 week MA | $1.42 | 87% below |
MGRX is in a downtrend: it's below all four of its weekly moving averages, and 87% below its 100-week average.
MGRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $37.2 | $4.15 | -89% |
| 2024 | $4.15 | $2.60 | -37% |
| 2025 | $2.60 | $0.71 | -73% |
| 2026 YTD | $0.71 | $0.18 | -75% |
MGRX has finished every year since 2023 lower, and it's down 75% so far in 2026.